Risk and prognosis of  bacteremia among individuals with and without end-stage renal disease: a Danish, population-based cohort study by unknown
Nielsen et al. BMC Infectious Diseases  (2015) 15:6 
DOI 10.1186/s12879-014-0740-8RESEARCH ARTICLE Open AccessRisk and prognosis of Staphylococcus aureus
bacteremia among individuals with and
without end-stage renal disease: a Danish,
population-based cohort study
Lise H Nielsen1*, Søren Jensen-Fangel1, Thomas Benfield2,3, Robert Skov4, Bente Jespersen5, Anders R Larsen4,
Lars Østergaard1, Henrik Støvring6, Henrik C Schønheyder7 and Ole S Søgaard1Abstract
Background: Staphylococcus aureus is a leading cause of bloodstream infections among hemodialysis patients and
of exit-site infections among peritoneal dialysis patients. However, the risk and prognosis of Staphylococcus aureus
bacteremia among end-stage renal disease patients have not been delineated.
Methods: In this Danish nationwide, population-based cohort study patients with end-stage renal disease and
matched population controls were observed from end-stage renal disease diagnosis/sampling until first episode of
Staphylococcus aureus bacteremia, death, or end of study period. Staphylococcus aureus positive blood cultures,
hospitalization, comorbidity, and case fatality were obtained from nationwide microbiological, clinical, and
administrative databases. Incidence rates and risk factors were assessed by regression analysis.
Results: The incidence rate of Staphylococcus aureus bacteremia was very high for end-stage renal disease patients
(35.7 per 1,000 person-years; 95% CI, 33.8-37.6) compared to population controls (0.5 per 1,000 person-years; 95% CI,
0.5-0.6), yielding a relative risk of 65.1 (95% CI, 59.6-71.2) which fell to 28.6 (95% CI, 23.3-35.3) after adjustment for
sex, age, and comorbidity. After stratification for type of renal replacement therapy, we found the highest incidence
rate of Staphylococcus aureus bacteremia among hemodialysis patients (46.3 per 1,000 person-years) compared to
peritoneal dialysis patients (22.0 per 1,000 person-years) and renal transplant recipients (8.9 per 1,000 person-years).
In persons with Staphylococcus aureus bacteremia, ninety-day case fatality was 18.2% (95% CI, 16.2%-20.3%) for
end-stage renal disease patients and 33.7% (95% CI, 30.3-37.3) for population controls.
Conclusions: Patients with end-stage renal disease, and hemodialysis patients in particular, have greatly increased
risk of Staphylococcus aureus bacteremia compared to population controls. Future challenges will be to develop
strategies to reduce Staphylococcus aureus bacteremia-related morbidity and death in this high-risk population.
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Bacteremia in hemodialysis and renal transplant patients
is most commonly caused by Staphylococcus aureus
(SA) [1-6]. SA is also the leading cause of peritoneal dia-
lysis catheter exit-site infections and is also frequently
the cause of peritoneal dialysis-related peritonitis [7]. In
addition, SA bacteremia (SAB) is associated with severe
complications such as endocarditis, osteomyelitis, pneu-
monia, and meningitis – conditions that are often fatal
despite relevant antibiotic treatment [8-12].
Use of intravascular catheters, fluid overload, accumu-
lation of dialysis fluid in the abdomen affecting the lung
volume, and the negative impact of the uremic state on
immune function, are all potential factors for bacteremia
among dialysis patients [13,14]. In renal transplant recip-
ients, immunosuppressive therapy as well as frequent
urinary tract infections may increase the risk of SAB
[15]. Although SAB is relatively common among end-
stage renal disease (ESRD) patients, case fatality in pa-
tients with SAB as well as risk factors associated with
SAB are not well characterized.
The objectives of this study were to: 1) investigate and
compare the incidence of SAB among ESRD patients to
that of population controls in Denmark; 2) estimate the
risk of SAB according to renal replacement therapy
(RRT) (dialysis patients and renal transplant recipients);
3) identify risk factors for SAB within the ESRD popula-
tion; and 4) estimate the case fatality rate following SAB.
Methods
Study design and population
We performed a nationwide, population-based cohort study
among ESRD patients and matched population controls in
the period 1 January 1992 to 31 December 2009. This study
was facilitated by the prospective registration of ESRD pa-
tients in Denmark that has been available in the Danish
Nephrology Registry (DNR) since 1 January 1990 [16].
We defined patients with ESRD as patients who had
been on continuous dialysis for at least 90 days or patients
with a renal graft. The estimated prevalence of ESRD in
Denmark is 0.08% [16]. ESRD patients who were at least
16 years of age and had no prior recorded SAB episode at
the time of ESRD diagnosis were included in the study.
For ESRD patients the follow-up period were stratified
according to the type of renal replacement therapy:
peritoneal dialysis, hemodialysis, or renal transplantation.
Patients whose type of renal replacement therapy was
altered during the study period (e.g. from hemodialysis to
renal transplantation) could contribute risk time to more
than one of the subgroups.
Population controls
Individuals with no diagnosis of ESRD were sampled
from the Danish Civil Registration System (CRS) andused for comparative analyses. To allow for comparisons
of rare events, we identified for each ESRD patient 19
population controls matched on gender and age (month
and year of birth) on the day the corresponding patient
was diagnosed with ESRD.
Data sources
For this study, we linked five nationwide databases using
the unique person identifier assigned by the Danish Civil
Registration System: the Danish Nephrology Registry
(DNR), the Danish Civil Registration System (CRS), the
Danish National Patient Registry (DNPR), the Danish
Registry of Causes of Death (DRCD), and the Danish
Staphylococcal Bacteremia Database.
The Danish Nephrology Registry (DNR)
All nephrology departments in Denmark that provide care
for patients with ESRD have been required to report cli-
nical and treatment data identifiable by CRS number to
the DNR database since 1 January 1990 [16]. Treatment of
patients with ESRD is centralized to 15 Departments of
Nephrology, four of which had status as transplantation
centres during the study period.
The Danish Civil Registration System (CRS)
The CRS, a national registry of all Danish residents, was
used to obtain information on date of birth, sex, date of
emigration, and date of death. Through CRS, multiple
registrations of the same patient were prevented as all
individuals are assigned a unique person identifier, which
allows accurate linkage across all the five registries [17].
The Danish National Patient Registry (DNPR)
The DNPR has collected nationwide data on all hospital
admissions since 1977. For each hospitalization, the
DNPR records the personal identification number (CRS
number), hospital department involved, discharge diag-
noses, and dates of admission and discharge. From 1977
to 1993, diagnosis codes were coded with reference to
the 8th revision of the International Classification of
Diseases (ICD-8); since 1994, they have been coded with
reference to the 10th revision (ICD-10). The treating
physician registered the final diagnosis codes at the time
of discharge.
The Danish National Diabetes Register (DNDR)
The DNDR contains nationwide information about dia-
betic patients in Denmark.
The registry is based on data from the DNPR, the
National Health Insurance Service Registry, the Register
of Medical Product Statistics, and the CRS. Main vari-
ables include: civil registration, gender, residence, date
and cause of inclusion. Data have been collected from
1996 onwards [18].
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Registration of SAB cases has been carried out since 1956
at the Staphylococcal Laboratory at the Statens Serum
Institut (SSI), Copenhagen. The Staphylococcal Laboratory
receives blood culture isolates from >95% cases of SAB
identified by the Departments of Clinical Microbiology in
Denmark for typing and national surveillance of antimicro-
bial susceptibility. All samples for SAB were required on
clinical indication. No screening for SAB was performed
during the study period. The database has been described
in detail elsewhere [9,10,19]. We included the following
data from this database in our study: the date of the first
blood culture positive for Staphylococcus aureus, methi-
cillin susceptibility of the isolated strain, and origin of
bacteremia (hospital associated or community acquired).
Hospital-acquired SAB was defined as SAB diagnosed
more than 48 hours after admission or catheter-related in-
fections. Health care-associated SAB included individuals
in regular hemodialysis or regular intravenous infusions of
chemotherapy or antivirals. Community acquired SAB was
defined as SAB diagnosed <48 hours after hospital admis-
sion with none of the above-mentioned health-care related
exposures. If a patient had recurrent SABs in the study
period, only the first episode was included in our study to
eliminate bias by multiple SAB episodes occurring in
highly susceptible individuals.
Data on comorbidity
The CCI includes 19 major disease categories and has
been adapted and validated for use with hospital discharge
data in ICD databases. The CCI is considered a reliable
method for measuring comorbidity in clinical research
[20]. In this study, we calculated a modified Charlson co-
morbidity index (m-CCI) score for each study participant
based on the complete hospital discharge history. The
m-CCI score did not include renal disease or diabetes




ESRD patients were observed from the date of initiating
RRT. Population controls entered the study on the same
day as their matched ESRD patient. We determined time
at risk from the date of first observation until the date of
death, emigration, first SAB, or 31 December 2009,
whichever came first.
Incidence rate (IR) and incidence rate-ratio (IRR)
The IR of first-time SAB was calculated for ESRD pa-
tients and compared to the IR for population controls.
Poisson regression analysis was used to determine IRs
and IRRs.Risk factors
Cox regression was used to determine hazard ratios and
identify risk factors for the first episode of SAB in ESRD
patients. The following variables were entered into the
model: gender, cause of ESRD (glomerulonephritis, dia-
betes (DM) type I and II, chronic interstitial nephritis
(CIN), hypertensive kidney disease, polycystic kidney
disease, nephrosclerosis, and vasculitis), and the follo-
wing time-varying covariates (TVCs): age (<50 years,
50–59 years, and ≥60 years), replacement therapy (trans-
plantation, hemodialysis, and peritoneal dialysis), and cal-
endar period (1992–1996, 1997–2001, 2002–2006, and
2007–2009). Comorbidity as assessed by the m-CCI score
was calculated for each patient on the date of their study
entry. Three comorbidity levels were defined according to
the m-CCI score: 0 = low, 1–2 =medium, and ≥3 = high.
Origin of SAB and methicillin resistance
The origin of incident SAB cases was tabulated (hospital
associated or community acquired) as well as the sus-
ceptibility of the isolated strains to methicillin (resistant,
sensitive, or unknown).
Case fatality rates following SAB
We computed Kaplan-Meier estimates for the 30- and
90-day case fatality rate of patients according to RRT and
their matched population controls. The resulting survival
curves were examined for differences by log-rank test. We
used Stata software, version 12.0 (StataCorp, College
Station, TX, USA) for statistical analyses. The study was
approved by the Danish Data Protection Agency (record
no. 2010-41-4935) and the Danish Health and Medicines
Agency (record no. 2010-331-0462).
Results
The study population encompassed 10,908 ESRD pa-
tients and 189,850 population controls, providing 39,478
and 1,338,339 person-years of follow-up (PYFU), re-
spectively. Median years of follow-up were 2.3 (IQR:
0.8–5.1) among ESRD patients and 6.4 (IQR: 2.9–10.5)
among population controls (Table 1). We identified a
total of 1,408 first episodes of SAB in ESRD patients and
733 first episodes of SAB in population controls.
Incidence rates and relative risk of SAB
The overall IR of first-time SAB was 35.7 per 1,000 PYFU
(95% confidence interval (CI), 33.8–37.6) for ESRD pa-
tients and 0.5 per 1,000 PYFU (95% CI, 0.5–0.6) for popu-
lation controls, yielding an unadjusted incidence rate-ratio
[21] of 65.1, (95% CI, 59.6–71.2). When controlling for
potential confounders including sex, age, diabetes melli-
tus, and m-CCI, we found an adjusted IRR of 28.6 (95%
CI, 23.3–35.3) for first-time SAB comparing ESRD pa-
tients with population controls. Stratified by mode of RRT,
Table 1 Characteristics of patients with end-stage renal





Median years of follow-up,
(interquartile range)
2.3 (0.8–5.1) 6.4 (2.9–10.5)
Age at entry (N = 200,758)
16-49 2,481 (22.7%) 39,901 (21.0%)
50-64 3,314 (30.4%) 57,471 (30.3%)
65+ 5,113 (46.9%) 92,478 (48.7%)
Sex (N = 200,758)
Female 4,059 (37.2%) 71,664 (37,7%)
Male 6,849 (62.8%) 118,186 (62.3%)
Diabetes (N = 200,758)
No 8,443 (77.4%) 180,475 (95.1%)
Yes 2,465 (22.6%) 9,375 (4.9%)
m-CCI score (N = 200,758)
Low 3,145 (28.8%) 133,599 (70.4%)
Moderate 4,232 (38.8%) 43,923 (23.14%)
High 3,531 (32.4%) 12,328 (6.5%)
SAB event (N = 200,758)
No 9,500 (87.1%) 189,117 (99.6%)
Yes 1,4081 (12.9%) 733 (0.4%)
ESRD: end-stage renal disease; m-CCI: modified Charlson Comorbidity Index;
SAB: Staphylococcal aureus bacteremia.
NOTE. Baseline characteristics. Data are no. of individuals, unless
otherwise indicated.
1Distribution of SAB events according to type of renal replacement therapy:
renal transplantation = 23 events, hemodialysis = 1,069 events, and peritoneal
dialysis = 316 events.
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PYFU for patients in hemodialysis, 22.2 (95% CI, 19.8–
24.8) per 1,000 PYFU for patients in peritoneal dialysis,
and 9.4 (95% CI, 6.0–14.2) per 1,000 PYFU for renal trans-
plant recipients. The corresponding unadjusted incidence
rate-ratios comparing ESRD patients with their respective
population controls were 78.3 (95% CI, 70.5–86.9) for
hemodialysis patients, 77.1 (95% CI, 31.4–189) for trans-
plant recipients, and 44.9 (95% CI, 37.7–53.4) for peri-
toneal dialysis patients.
The 1-year risk of SAB was 8.0% (95% CI, 7.5–8.5) for
ESRD patients and 0.05% (95% CI, 0.04–0.06) for popu-
lation controls. The corresponding 5-year risk of SAB
was 16.1% (95% CI, 15.2–17.0) for ESRD patients and
0.25% (95% CI, 0.23–0.28) for population controls.
Figure 1 shows the association between calendar time
and risk of SAB over the entire study period (year 1992–
2009) for ESRD patients and population controls. The
risk of SAB decreased among ESRD patients regardless
of RRT mode as seen in Additional file 1. The risk of
SAB among population controls increased slightly froman IR of 0.3 per 1,000 PYFU (95% CI, 0.2–0.4) in the
first calendar period (years 1992–1996) to an IR of 0.6
per 1,000 PYFU (95% CI, 0.6–0.7) in the last calendar
period (years 2007–2009).
Risk factors among persons with ESRD
Table 2 illustrates potential risk factors for a first-time
SAB among ESRD patients. In the analysis we adjusted
for sex, age, diabetes, m-CCI, calendar period, cause of
ESRD, and type of RRT. Factors associated with a sig-
nificantly increased risk of SAB were high vs. low m-CCI
score (HR = 1.6 [95% CI, 1.4–1.9]), hemodialysis (HR = 5.4
[95% CI, 4.1–7.1]), and peritoneal dialysis (HR = 2.1 [95%
CI, 1.5–2.9]) compared to renal transplantation as mode
of RRT. Moreover, the risk of SAB declined during the
study period.
Characteristics of SAB
Origin of SAB – hospital associated or community
acquired-among ESRD patients are shown in Table 3.
Where the frequency of hospital associated-SAB infec-
tions among ESRD patients was high (67.2%), the overall
proportion of methicillin-resistant SA (MRSA) was low.
Only 8 (0.7%) of the 995 tested strains were caused by
MRSA in the entire study population (6 among ESRD
patients and 2 among population controls).
Frequent complications following SAB were endocar-
ditis and osteomyelitis. Endocarditis occurred in 3.1%
among ESRD patients and in 5.7% among population
controls. Osteomyelitis occurred in 3.0% among ESRD
patients and in 9.1% among population controls.
Case fatality following SAB
The case fatality following SAB for ESRD patients and
population controls is shown in Figure 2. In ESRD pa-
tients, the 30-day case fatality rate after a diagnosis of SAB
was 9.4% (95% CI, 8.0–11.1) compared with 24.2% (95%
CI, 21.2–27.6) among population controls. The 90-day
case fatality rate among ESRD patients was 18.2% (95%
CI, 16.2–20.3) compared with 33.7% (95% CI, 30.3–37.3)
among population controls. Stratified by RRT, the 30-day
case fatality rate was 7.4% (95% CI, 5.0–10.9) among
patients receiving peritoneal dialysis, 10.2% (95% CI,
8.5–12.1) among patients receiving hemodialysis, and
4.4% (95% CI, 0.6–27.1) among renal transplant recipients.
Ninety-day case fatality rates were 14.5% (95% CI, 11.0–
18.9) among patients receiving peritoneal dialysis, 19.5%
(95% CI, 17.3–22.1) among patients receiving hemo-
dialysis, and 4.4% (95% CI, 0.6–27.1) among renal trans-
plant recipients.
Discussion
The present study is the first to investigate, on a national
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Figure 1 Incidence rates stratified by renal replacement therapy during the study period from 1992–2009.
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time SAB to be 65-fold higher among ESRD patients
compared to population controls. Even after adjusting
for sex, age, diabetes mellitus, and m-CCI the risk was
28-fold higher in ESRD patients compared to population
controls. Hemodialysis patients in particular had a
greatly increased risk of SAB. Nevertheless, the inci-
dence of SAB declined throughout the study period pos-
sibly indicating enhanced compliance with infection
control precautions by both patients and staff. The rea-
sons for this decline are unknown and could be do to
changes in the virulence or other genetic attributes in
circulating strains of Staphylococcus aureus. The reasons
for this decline are unknown and could be do to changes
in the virulence or other genetic attributes in circulating
strains of Staphylococcus aureus [22]. In addition, we
identified characteristics, e.g. high m-CCI score and
hemodialysis among ESRD patients that may be selec-
tively targeted for interventions to further reduce the
risk of SAB.
The strengths of our study include the use of population-
based, nationwide cohorts with inclusion of all adults re-
ceiving RRT (transplant recipients, and patients receiving
hemodialysis or peritoneal dialysis) in an entire country,
minimal loss to follow-up, and the availability of compre-
hensive hospitalization data and microbiological data on
each SAB case. The m-CCI enabled us to adjust for under-
lying diseases, and the large study size provided statisticalprecision for the estimates. Because we only included the
first blood cultures positive for Staphylococcus aureus in
the analyses, our estimates were not biased by multiple
SAB episodes occurring in highly susceptible individuals.
A number of factors may influence the increased risk
of SAB in ESRD patients that we observed in this study.
As reported in previous studies [2,23], we found that
older age, male gender and underlying comorbid medical
conditions increased the risk of SAB. Furthermore a
wider use of immunosuppressive therapy among ESRD
patients may contribute to a higher risk of SAB [9].
We found that SAB was hospital associated in 67.2%
of cases among ESRD patients and 57.7% among popula-
tion controls. Previous results have documented that the
incidences of both hospital associated and community
acquired SAB have been increasing [9]. In Denmark,
compared to hospital acquired SAB, community ac-
quired SAB has increased relatively more and has a
higher case fatality rate among adults [9]. Increased case
fatality among population controls compared with ESRD
patients can be explained by various reasons including;
early diagnose of SAB among ESRD patients, especially
hemodialysis patients, who visits the dialysis clinics
several times during a week, increased awareness of fe-
verish disease in ESRD patients, and the fact that dialysis
catheter exit-site infections are the cause of a high
amount of the acquired infections, which thereby have a
better prognosis because of immediate catheter removal.
Table 2 Hazard Ratios for first Staphylococcus aureus bacteremia among patients with end-stage renal disease
according to potential risk factors
Unadjusted Adjusted*
Characteristic HR (95% CI) HR (95% CI) P value (in adjusted analysis)
Sex
Female 1 (Reference) 1 (Reference)
Male 1.12 (1.00–1.24) 1.08 (0.96–1.20) 0.20
Age
<50 years 1 (Reference) 1 (Reference)
50-64 years 1.02 (0.90–1.16) 0.87 (0.76–1.00) 0.06
≥65 years 1.09 (0.96–1.25) 0.87 (0.75–1.00) 0.06
Diabetes mellitus
No 1 (Reference) 1 (Reference)
Yes 1.33 (1.18–1.50) 1.05 (0.91–1.22) 0.52
m-CCI
Low 1 (Reference) 1 (Reference)
Moderate 1.33 (1.15–1.54) 1.20 (1.03–1.40) 0.02
High 1.86 (1.62–2.14) 1.61 (1.37–1.91) <0.001
Calendar period
1992–1996 1 (Reference) 1 (Reference)
1997–2001 0.92 (0.80–1.06) 0.86 (0.75–0.98) 0.03
2002–2006 0.81 (0.70–0.93) 0.72 (0.62–0.83) <0.001
2007–2009 0.78 (0.64–0.94) 0.69 (0.57–0.84) <0.001
Cause of ESRD
Glomerulonephritis 1 (Reference) 1 (Reference)
Diabetes mellitus 1.55 (1.29–1.86) 1.77 (0.95–1.45) 0.13
CIN 1.05 (0.84–1.31) 0.98 (0.78–1.22) 0.85
Hypertensive kidney 1.24 (1.04–1.48) 1.15 (0.96–1.38) 0.12
Polycystic kidney 0.55 (0.41–0.74) 0.54 (0.40–0.72) <0.001
Vasculitis 1.42 (1.06–1.90) 1.25 (0.92–1.68) 0.15
Other 1.19 (0.94–1.52) 1.09 (0.85–1.40) 0.50
Renal replacement therapy
Transplantation 1 (Reference) 1 (Reference)
Hemodialysis 3.95 (3.34–4.68) 5.41 (4.13–7.09) <0.001
Peritoneal dialysis 0.58 (0.51–0.65) 2.07 (1.46–2.95) <0.001
*Adjusted for sex, age, diabetes, modified Charlson Comorbidity Index, calendar period, cause of ESRD, and renal replacement therapy. m-CCI score categories
low = 0-1, moderate = 2-3, and high > 3. HR: hazard ratio; CI: confidence interval; m-CCI: modified Charlson Comorbidity Index; ESRD: end-stage renal disease.
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complications among persons with community acquired
SAB compared to hospital acquired SAB which also may
explain the relatively high case fatality rate among the
population with SAB in our study [24,25].
We observed low rates of MRSA in the study po-
pulation, which correlates well with previous findings
[4,9,23]. However, the incidence of MRSA infections in
the general population has increased in Denmark duringthe later years [26], i.e. after the end of our study period
(2009).
Some limitations of this study may have impacted our
findings. Physicians may have a lower threshold for hos-
pital admission of ESRD and for ordering blood cultures
in patients with signs and symptoms compatible with
SAB than for patients who did not undergo RRT, which
could cause us to overestimate the relative risk of SAB
in ESRD patients. In fact, we found a lower case fatality
Table 3 Characteristics of patients with Staphylococcal
aureus bacteremia
Characteristics ESRD Population controls
Origin of infection
Community acquired 60 (5.08%) 193 (33.6%)
Hospital associated 794 (67.2%) 331 (57.7%)
Unknown 328 (27.8%) 50 (8.7%)
Methicillin category
Methicillin sensitive 815 (99.3%) 272 (99.3%)
Methicillin resistant 6 (0.7%) 2 (0.7%)
Complications
None/not registered 717 (93.1%) 224 (84.5%)
Endocarditis 24 (3.1%) 15 (5.7%)
Osteomyelitis 23 (3.0%) 24 (9.1%)
Meningitis* 6 (0.8%) 2 (0.6%)
NOTE. No. of individuals (%). ESRD: end-stage renal disease *from 1990.
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trols. This may indicate that, for some ESRD patients,
the severity and complications of SAB upon hospital
admission are less than in the matched population
controls – possibly due to more closely monitoring for
blood stream infection. A severity index score could not
be calculated from this dataset, thus changes in disease
severity during the study period could not be assessed or
analysed. Furthermore, we only included cases with SA
positive blood culture; hence the true incidence of inva-
sive SA disease may have been underestimated. Also,
coding errors may occur in routine hospital discharge
data, leading to misclassifications in both the ESRD
group and population control group. Furthermore, we
did not have any data on type of dialysis access. Our
data does not reflect the total burden of SAB in the
study population (since only first episodes of SAB were
included). Finally, we had no information on immuno-
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Figure 2 90-day case fatality following SAB in ESRD patients
and population controls.individual drugs on SAB. According to other studies [15]
risk of infection is not significantly different for specific
immunosuppressive drug regimens.Conclusions
In conclusion, patients receiving RRT for ESRD, and
hemodialysis patients in particular, have a greatly in-
creased risk of SAB compared to population controls.
SAB was associated with significant case fatality both in
ESRD patients and in population controls. As there are
currently no prophylactic vaccines for SA, future chal-
lenges will be to develop other preventive measures and
treatment strategies to reduce morbidity and case fatality
from SAB in high-risk populations such as ESRD pa-
tients in general, and hemodialysis patients in particular.Additional file
Additional file 1: Incidence rate of first episode of SAB according to
type of renal replacement therapy. Additional table showing incidence
rates and incidence rate ratios after first episode of Staphylococcus aureus
bacteremia according to type of renal replacement therapy; renal
transplant recipients, hemodialysis patients or peritoneal dialysis patients.Competing interests
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